Traumatic brain injuries (TBIs) are clinically grouped by severity: mild, moderate and severe.
Mild TBI (the least severe form) is synonymous with concussion and is typically caused by …

Severe traumatic brain injury (TBI) is currently managed in the intensive care unit with a
combined medical–surgical approach. Treatment aims to prevent additional brain damage …

Axonal injury is a key determinant of long-term outcomes after traumatic brain injury (TBI) but
has been difficult to measure clinically. Fluid biomarker assays can now sensitively quantify …

Objective: To image β-amyloid (Aβ) plaque burden in long-term survivors of traumatic brain
injury (TBI), test whether traumatic axonal injury and Aβ are correlated, and compare the …

Diffuse axonal injury (DAI) is an important cause of morbidity in patients with traumatic brain
injury (TBI). There is currently no simple and reliable technique for early identification of …

The majority of clinical trials targeting the tau protein in Alzheimer's disease and other
tauopathies are tau immunotherapies. Because tau pathology correlates better with the …

The early molecular response to severe traumatic brain injury (TBI) was evaluated using
biopsies of structurally normal-appearing cortex, obtained at location for intracranial …

Moderate to severe traumatic brain injuries (TBI) require treatment in an intensive care unit
(ICU) in close collaboration of a multidisciplinary team consisting of different medical …

Neuroinflammation has been reported to be associated with white matter injury (WMI) after
subarachnoid hemorrhage (SAH). As the main resident immune cells of the brain, microglia …

Recent evidence of short-term alterations in brain physiology associated with repeated
exposure to moderate intensity subconcussive head acceleration events (HAEs), prompts …